Sagimet stock surges on positive acne trial data

Sagimet Biosciences Inc Series A (NASDAQ:SGMT) shares surged over 12% in premarket trading on Wednesday after receiving positive results from its license partner Ascletis' Phase 3 open-label extension trial of denifanstat for moderate to severe acne. The trial demonstrated that denifanstat achieved a 57% treatment success rate, with significant reductions in total lesions (72%) and inflammatory lesions (77%) after 52 weeks of treatment.

The drug was also generally well-tolerated, with no adverse event-related permanent discontinuations.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.